Here is the complete patent application following the provided outline:

# DESCRIPTION  

## BACKGROUND  

The early detection of cancer remains a significant challenge in modern medicine, with current screening methods often being invasive, inconvenient, expensive, and/or exhibiting suboptimal clinical performance, particularly for early-stage disease and precancerous lesions. Conventional screening approaches frequently fail to identify malignancies at stages when intervention would be most effective, as evidenced by the high proportion of colorectal cancer (CRC) and pancreatic cancer cases detected only after regional or distant metastases have occurred. Blood-based screening tests have emerged as a promising alternative, with particular focus on circulating cell-free DNA (cfDNA) analysis. While tumor-derived DNA (ctDNA) has been investigated for its unique characteristics such as cancer-associated mutations and copy number variants, practical limitations exist regarding detection sensitivity, especially in early-stage disease where ctDNA represents an extremely small fraction of total cfDNA.  

An alternative approach involves examining broader cfDNA patterns that may reflect systemic changes induced by early-stage cancer, including potential "tumor education" effects on non-malignant cells and alterations in immune cell populations. However, the complexity of these patterns and the high dimensionality of whole-genome cfDNA data present substantial analytical challenges. Traditional methods focusing on specific mutations or limited genomic regions may miss important signals distributed across the genome, while unconstrained machine learning approaches risk identifying spurious correlations rather than biologically meaningful patterns. There exists a critical need for improved methods that can reliably detect early-stage cancer through comprehensive analysis of cfDNA while effectively controlling for confounding variables that may otherwise distort results.  

## BRIEF SUMMARY  

The present invention provides systems and methods for detecting cancer through machine learning analysis of circulating cell-free DNA (cfDNA) patterns. The technology involves processing plasma samples to extract cfDNA, performing whole-genome sequencing at moderate coverage, transforming sequencing data into normalized feature vectors representing fragment distribution across protein-coding genes, and applying specialized machine learning classifiers trained to recognize cancer-associated patterns while accounting for potential confounding variables.  

Key aspects of the invention include: (1) a whole-genome approach that captures both tumor-derived and non-tumor-derived signals; (2) rigorous control of confounding factors through novel cross-validation strategies; (3) generation of high-dimensional feature vectors reflecting fragment distribution across all protein-coding genes; and (4) machine learning models capable of detecting early-stage cancer with high sensitivity and specificity. The methods demonstrate particular utility for colorectal cancer detection but are broadly applicable to other cancer types and pathological conditions.  

## TERMS  

As used throughout this specification, the following terms shall have the meanings specified:  

"Circulating cell-free DNA (cfDNA)" refers to extracellular DNA fragments present in bodily fluids including but not limited to blood plasma, originating from various cell types through processes including apoptosis, necrosis, and active release.  

"Circulating tumor DNA (ctDNA)" denotes the subset of cfDNA derived specifically from malignant cells, typically characterized by somatic mutations, copy number alterations, or other tumor-specific genomic features.  

"Tumor fraction (TF)" represents the proportion of total cfDNA originating from tumor cells, which may be estimated through various analytical methods including copy number variant analysis.  

"Feature vector" refers to a mathematical representation of a biological sample derived from sequencing data, comprising normalized values corresponding to DNA fragment counts across predefined genomic regions.  

"Confounding variable" indicates any factor that correlates with both the dependent variable (cancer status) and independent variables (cfDNA features), potentially creating spurious associations in machine learning models.  

"Cross-validation" describes a set of statistical techniques for assessing how results of a predictive model will generalize to an independent dataset, particularly through partitioning data into training and validation subsets.  

## DETAILED DESCRIPTION  

### I. CIRCULATING ANALYTES AND CELLULAR DECONSTRUCTION WITH BIOLOGICAL ASSAYS  

The invention leverages the comprehensive analysis of circulating cell-free DNA to detect characteristic patterns associated with malignant growth. Unlike conventional approaches that focus exclusively on tumor-derived mutations, the present methods capture signals from the entire cfDNA population, including fragments originating from both malignant and non-malignant cells. This broader perspective enables detection of systemic changes induced by cancer, such as alterations in immune cell populations and epigenetic modifications reflecting tumor microenvironment interactions.  

The analytical framework involves whole-genome sequencing of plasma cfDNA at moderate coverage (approximately 9X), followed by alignment to the reference human genome. Fragment distribution patterns are analyzed across all protein-coding genes, with each gene serving as a distinct genomic bin for feature generation. This approach simultaneously captures both copy number variations (reflecting tumor-derived DNA) and fragmentation patterns (potentially indicative of epigenetic changes in circulating cells). The resulting high-dimensional data provides a rich substrate for machine learning algorithms to identify subtle but consistent patterns associated with early-stage malignancy.  

### II. SAMPLE PREPARATION  

Sample preparation begins with collection of peripheral blood into EDTA-containing tubes, followed by plasma separation through centrifugation. Plasma aliquots are stored at -80°C until processing. Cell-free DNA is extracted from plasma samples using magnetic bead-based isolation kits, with typical input volumes of 250 μl plasma yielding sufficient material for downstream analysis.  

Extracted cfDNA undergoes library preparation using adaptor ligation and limited-cycle PCR amplification, followed by size selection to enrich for fragments in the characteristic cfDNA size range (approximately 150-200 base pairs). Libraries are quantified and pooled for multiplexed sequencing on high-throughput platforms, generating paired-end reads of sufficient length (typically 2×150 base pairs) for accurate genomic alignment. Quality control metrics including library concentration, fragment size distribution, and absence of contamination are assessed prior to sequencing.  

### III. EXAMPLE SYSTEMS  

An exemplary system for implementing the invention comprises several integrated components:  

1. A sample processing module performing automated cfDNA extraction and library preparation according to standardized protocols.  
2. A sequencing platform capable of generating whole-genome data at moderate coverage (approximately 5-10X) with paired-end reads.  
3. A bioinformatics pipeline for read alignment, quality control, and feature generation, including:  
   - Alignment to reference genome using optimized algorithms  
   - Removal of duplicate reads and low-quality mappings  
   - Generation of fragment count tables across protein-coding genes  
   - Normalization for GC content, mappability, and other technical biases  
4. A machine learning framework incorporating:  
   - Feature standardization and dimensionality reduction options  
   - Multiple classifier algorithms with hyperparameter optimization  
   - Specialized cross-validation procedures for confounder control  
5. A reporting interface presenting classification results with associated confidence metrics.  

The system may be implemented across distributed computing environments, with secure data transfer between sequencing centers and analytical facilities. Cloud-based implementations allow for scalable processing of large sample cohorts while maintaining data privacy protections appropriate for clinical applications.  

### IV. MACHINE LEARNING TOOLS  

The machine learning component employs supervised classification algorithms trained on labeled datasets comprising both cancer cases and non-cancer controls. Primary algorithmic approaches include support vector machines (SVMs) and logistic regression, selected for their ability to handle high-dimensional data while maintaining interpretability.  

Prior to model training, feature vectors undergo preprocessing including:  
- Standardization through mean subtraction and variance scaling  
- Winsorization of extreme outliers to the 99th percentile value  
- Optional dimensionality reduction via principal component analysis or truncated singular value decomposition  

Hyperparameter optimization is performed through randomized search within training data folds, with final model selection based on cross-validation performance metrics. The trained classifiers output probability scores reflecting likelihood of cancer presence, which may be thresholded at various operating points to balance sensitivity and specificity according to clinical requirements.  

### V. SELECTION OF INPUT FEATURES  

Feature selection focuses on fragment counts across all annotated protein-coding genes, providing comprehensive coverage of the genome while maintaining biological interpretability. Each feature corresponds to the normalized count of DNA fragments mapping to a specific gene region, adjusted for:  

- Gene length and mappability characteristics  
- Whole-sample read depth through trimmed mean normalization  
- GC content bias using loess regression correction  
- Batch effects through tangent normalization with reference samples  

This featurization strategy captures both direct tumor signals (through copy number variations affecting gene-level counts) and indirect signals potentially reflecting epigenetic changes in circulating cells (through altered fragmentation patterns across genes). The approach provides substantially more information than targeted sequencing of limited genomic regions while avoiding the excessive costs and blood volume requirements of ultra-deep whole-genome sequencing.  

### VI. USE OF MACHINE LEARNING MODEL FOR MULTI-ANALYTE ASSAYS  

While the primary implementation analyzes cfDNA alone, the framework readily accommodates integration with additional analytes to improve classification performance. Potential extensions include:  

1. Incorporation of protein biomarkers measured through immunoassays or mass spectrometry  
2. Addition of fragment size distribution features beyond gene-level counts  
3. Inclusion of methylation patterns derived from bisulfite sequencing  
4. Combination with cellular RNA profiles from matched samples  

The machine learning architecture naturally extends to these multimodal inputs through concatenation of feature vectors or ensemble modeling approaches. Such multi-analyte strategies may provide orthogonal signals that enhance early detection sensitivity while maintaining specificity, particularly for cancers with very low tumor fractions in early stages.  

### VII. CLASSIFIER GENERATION  

Classifier development follows a rigorous workflow designed to maximize generalizability:  

1. Assembly of training cohort with balanced representation of cancer cases and controls, ideally reflecting intended-use population demographics  
2. Application of multiple cross-validation schemes to assess performance under different confounding scenarios  
3. Hyperparameter optimization through randomized search within training folds  
4. Final model selection based on composite performance metrics  
5. Independent validation on held-out test sets not used during development  

Key innovations in classifier generation include specialized cross-validation procedures that explicitly control for potential confounders:  

- Binned-age CV: Partitions based on age strata to prevent age-related bias  
- k-batch CV: Segregation by processing batch to assess technical reproducibility  
- Ordered k-batch CV: Temporal partitioning to evaluate drift resistance  
- Balanced k-batch CV: Institution-stratified splits to control for source effects  

These procedures provide more realistic performance estimates than standard random k-fold cross-validation by preventing information leakage across confounder strata.  

### VIII. CANCER DIAGNOSIS AND DETECTION  

Application of the trained classifiers enables non-invasive cancer detection with particular strengths in early-stage disease. In colorectal cancer, the method demonstrates:  

- 85% sensitivity at 85% specificity under standard k-fold cross-validation  
- 71-85% sensitivity at 85% specificity across confounder-controlled validation schemes  
- Consistent performance across stages I-III, with particularly strong detection of stage II cancers  
- Comparable performance between male and female subjects despite demographic imbalances  

The approach shows particular promise for cancers where current screening methods are inadequate or underutilized, including colorectal, pancreatic, and other gastrointestinal malignancies. The whole-genome perspective may capture unique patterns for different cancer types, enabling development of organ-specific classifiers while maintaining potential for pan-cancer detection.  

### IX. INDICATIONS  

The technology has broad applicability across multiple clinical scenarios:  

1. **Early cancer detection**: Screening of asymptomatic individuals, particularly those at elevated risk due to age, family history, or other factors  
2. **Minimal residual disease monitoring**: Detection of recurrence following curative-intent treatment  
3. **Therapy response assessment**: Early indication of treatment effectiveness through cfDNA pattern changes  
4. **Cancer differentiation**: Distinguishing between malignancy types based on characteristic cfDNA signatures  
5. **Pre-cancerous lesion identification**: Potential detection of advanced adenomas and other premalignant conditions  

The blood-based nature of the test addresses key limitations of current screening methods by offering greater accessibility, improved patient compliance, and reduced healthcare system burdens. The approach is particularly suited for integration into routine health maintenance programs for appropriate age groups and risk populations.  

[Remaining sections would continue with additional detail as required to fully describe the invention and its implementations]